ProQR (PRQR) CEO Daniel de Boer details long-dated option grants

Rhea-AI Filing Summary

ProQR Therapeutics N.V. Chief Executive Officer Daniel Anton de Boer has filed an initial ownership report listing a series of share options over Ordinary Shares. These options carry exercise prices between $0.66 and $15.78 per share, with expirations from 2026 through 2035. The filing shows existing option holdings only, with no open-market purchases or sales reported.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

de Boer Daniel Anton

(Last) (First) (Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN 2333 CK

(City) (State) (Zip)

NETHERLANDS

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

3a. Foreign Trading Symbol
[N/A]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(1)	12/31/2026	Ordinary Shares	239,717	$4.9	D
Share Option (Right to Buy)	(1)	12/31/2027	Ordinary Shares	379,285	$3.3	D
Share Option (Right to Buy)	(1)	12/31/2028	Ordinary Shares	253,192	$15.78	D
Share Option (Right to Buy)	(1)	12/31/2029	Ordinary Shares	395,561	$9.91	D
Share Option (Right to Buy)	(1)	12/31/2030	Ordinary Shares	442,279	$4.2	D
Share Option (Right to Buy)	(1)	02/29/2032	Ordinary Shares	450,051	$1.02	D
Share Option (Right to Buy)	(2)	05/31/2032	Ordinary Shares	1,200,000	$0.66	D
Share Option (Right to Buy)	(3)	12/31/2032	Ordinary Shares	442,182	$3.41	D
Share Option (Right to Buy)	(4)	12/31/2033	Ordinary Shares	479,171	$1.98	D
Share Option (Right to Buy)	(5)	12/31/2034	Ordinary Shares	463,587	$2.65	D
Share Option (Right to Buy)	(6)	09/22/2035	Ordinary Shares	1,400,000	$2.16	D
Share Option (Right to Buy)	(7)	12/31/2035	Ordinary Shares	595,644	$2.02	D

Explanation of Responses:

1. Fully vested.

2. 25% of the shares subject to such option vest and become exercisable on June 1, 2023, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

3. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

4. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

5. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

6. 25% of the shares subject to such option vest and become exercisable on September 23, 2026, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

7. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does ProQR (PRQR) CEO Daniel de Boer report in this Form 3?

Daniel de Boer reports his existing holdings of share options over ProQR Ordinary Shares. The filing lists multiple option grants with different exercise prices and expiration dates, providing a baseline view of his derivative ownership position as a company insider.

Does the ProQR (PRQR) Form 3 show any insider buying or selling?

No, the Form 3 does not show any insider buying or selling. It only discloses existing option positions, with transaction summaries indicating zero purchases, zero sales, and no exercises, gifts, or tax-withholding related dispositions.

What types of securities are disclosed for ProQR (PRQR) CEO in this filing?

The filing discloses “Share Option (Right to Buy)” derivative securities linked to ProQR Ordinary Shares. Each entry shows the exercise price, expiration date, and the number of underlying shares covered by the option, all held directly by Daniel de Boer.

Over what period do Daniel de Boer’s ProQR (PRQR) options expire?

The options disclosed in the filing have expiration dates ranging from the end of 2026 through the end of 2035. This schedule indicates a long-dated option portfolio that extends across multiple years of potential future exercisability.

Do the ProQR (PRQR) CEO’s options have vesting conditions?

Yes, footnotes describe vesting conditions for several option grants. Typically, 25% of the shares vest on a specified initial date, with the remaining 75% vesting in 12 substantially equal quarterly installments, contingent on continuous service with ProQR.

How are the ProQR (PRQR) CEO’s options structured in terms of exercise price?

The options span a range of exercise prices, from $0.66 per share up to $15.78 per share. Each grant’s exercise price is fixed in the filing, defining the cost per share if Daniel de Boer chooses to exercise those options in the future.